OncLive TV

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Andrew Davis, MD, discusses how antibody-drug conjugates could continue to reshape the breast cancer treatment paradigm.

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.

Nicole S. Evans, MD, discusses the influence of patient factors on declining treatment in pancreatic cancer.

Aditya Bardia, MD, MPH, FASCO, discusses HER2 IHC testing in patients with HER2-low and -ultralow metastatic breast cancer.

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.

Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.

Komal Jhaveri, MD, FACP, discusses the implications of the DESTINY-Breast06 trial for hormone receptor–positive, HER2-low and -ultralow breast cancer.

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Tycel Phillips, MD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Bhavana Pothuri, MD, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to MMR/MSI status.

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

David M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.